CN102892425A - 心脏病症的治疗 - Google Patents

心脏病症的治疗 Download PDF

Info

Publication number
CN102892425A
CN102892425A CN201180012769XA CN201180012769A CN102892425A CN 102892425 A CN102892425 A CN 102892425A CN 201180012769X A CN201180012769X A CN 201180012769XA CN 201180012769 A CN201180012769 A CN 201180012769A CN 102892425 A CN102892425 A CN 102892425A
Authority
CN
China
Prior art keywords
ser
lys
arg
glu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180012769XA
Other languages
English (en)
Chinese (zh)
Inventor
约根·索贝格·彼得森
安妮·路易斯·舍尔比
马里耶·斯科夫高
亨利克·迪尤隆德·彼得森
莱娜·阿克塞尔森
迪特·里贝尔
埃迪·迈尔
里·舒尔茨·汉森
克尔德·福斯格劳
比亚内·杜·拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102892425(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of CN102892425A publication Critical patent/CN102892425A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201180012769XA 2010-01-20 2011-01-20 心脏病症的治疗 Pending CN102892425A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
US61/296,657 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Publications (1)

Publication Number Publication Date
CN102892425A true CN102892425A (zh) 2013-01-23

Family

ID=43928934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180012769XA Pending CN102892425A (zh) 2010-01-20 2011-01-20 心脏病症的治疗

Country Status (15)

Country Link
US (1) US20130157953A1 (enExample)
EP (1) EP2525809B1 (enExample)
JP (2) JP2013517307A (enExample)
KR (1) KR20120128129A (enExample)
CN (1) CN102892425A (enExample)
AU (1) AU2011206979B2 (enExample)
BR (1) BR112012018104A2 (enExample)
CA (1) CA2786934A1 (enExample)
CL (1) CL2012002037A1 (enExample)
EA (1) EA026384B1 (enExample)
IL (1) IL220876A0 (enExample)
MX (1) MX342409B (enExample)
NZ (1) NZ601167A (enExample)
PH (1) PH12012501494A1 (enExample)
WO (1) WO2011088837A1 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068841A (zh) * 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
CN105829339A (zh) * 2013-11-06 2016-08-03 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
CN105849122A (zh) * 2013-11-06 2016-08-10 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
CN107250155A (zh) * 2014-12-30 2017-10-13 韩美药品株式会社 胰高血糖素衍生物
CN107636009A (zh) * 2014-12-30 2018-01-26 韩美药品株式会社 具有改善的稳定性的胰高血糖素衍生物
WO2019101036A1 (zh) * 2017-11-24 2019-05-31 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
US10981967B2 (en) 2015-12-31 2021-04-20 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
US11142559B2 (en) 2016-06-29 2021-10-12 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
WO2021227989A1 (zh) * 2020-05-09 2021-11-18 天津药物研究院有限公司 具有双受体激动作用的多肽衍生物及其用途
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
CN115304666A (zh) * 2017-11-24 2022-11-08 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
CA2767792A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
SG11201403377QA (en) * 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
IN2014MN02304A (enExample) 2012-05-03 2015-08-07 Zealand Pharma As
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014049610A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP3653649A1 (en) 2012-11-20 2020-05-20 Mederis Diabetes, LLC Improved peptide pharmaceuticals for insulin resistance
WO2014096179A1 (en) * 2012-12-19 2014-06-26 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
WO2014096149A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 Derivatives
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HRP20181505T1 (hr) 2013-10-17 2018-11-02 Zealand Pharma A/S Acilirani analozi glukagona
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2805326T3 (es) * 2014-10-10 2021-02-11 Novo Nordisk As Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
RU2735762C2 (ru) 2015-04-16 2020-11-06 Зилэнд Фарма А/С Ацилированный аналог глюкагона, его применение и способы получения
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017214543A1 (en) 2016-06-09 2017-12-14 Amidebio, Llc Glucagon analogs and methods of use thereof
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
EP3735295B1 (en) 2018-01-03 2024-08-21 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1421950A1 (en) * 2002-11-19 2004-05-26 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054594B1 (en) * 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
EP1950224A3 (en) 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
KR20090119876A (ko) * 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
NZ589847A (en) * 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1421950A1 (en) * 2002-11-19 2004-05-26 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068841A (zh) * 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
CN105829339B (zh) * 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
CN105829339A (zh) * 2013-11-06 2016-08-03 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
CN105849122A (zh) * 2013-11-06 2016-08-10 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
CN107250155A (zh) * 2014-12-30 2017-10-13 韩美药品株式会社 胰高血糖素衍生物
CN107636009A (zh) * 2014-12-30 2018-01-26 韩美药品株式会社 具有改善的稳定性的胰高血糖素衍生物
CN107250155B (zh) * 2014-12-30 2021-08-10 韩美药品株式会社 胰高血糖素衍生物
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
US11667688B2 (en) 2015-06-30 2023-06-06 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US10981967B2 (en) 2015-12-31 2021-04-20 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
US11332508B2 (en) 2015-12-31 2022-05-17 Hanmi Pharm. Co., Ltd. Triple glucagon/GLP-1/GIP receptor agonist
US11142559B2 (en) 2016-06-29 2021-10-12 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
WO2019101036A1 (zh) * 2017-11-24 2019-05-31 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN115304666A (zh) * 2017-11-24 2022-11-08 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
WO2021227989A1 (zh) * 2020-05-09 2021-11-18 天津药物研究院有限公司 具有双受体激动作用的多肽衍生物及其用途

Also Published As

Publication number Publication date
MX2012008440A (es) 2012-08-15
JP6200025B2 (ja) 2017-09-20
BR112012018104A2 (pt) 2017-10-17
US20130157953A1 (en) 2013-06-20
PH12012501494A1 (en) 2012-10-22
AU2011206979B2 (en) 2015-09-10
JP2016138127A (ja) 2016-08-04
NZ601167A (en) 2014-12-24
EA201290540A1 (ru) 2013-03-29
MX342409B (es) 2016-09-28
JP2013517307A (ja) 2013-05-16
EA026384B1 (ru) 2017-04-28
IL220876A0 (en) 2012-09-24
CA2786934A1 (en) 2011-07-28
EP2525809B1 (en) 2016-08-03
CL2012002037A1 (es) 2012-09-07
KR20120128129A (ko) 2012-11-26
AU2011206979A1 (en) 2012-08-02
WO2011088837A1 (en) 2011-07-28
EP2525809A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
JP6200025B2 (ja) 心臓病の処置
JP5937582B2 (ja) グルカゴン類似体
JP5635530B2 (ja) グルカゴン類似体
US8642541B2 (en) Glucagon analogues
JP5635529B2 (ja) グルカゴン類似体
JP5635532B2 (ja) グルカゴン類似体
CN104812772A (zh) 胰高血糖素类似物
JP2019112437A (ja) グルカゴン類似体
KR20140114845A (ko) 글루카곤 유사체
CN119119235A (zh) 酰化胰高血糖素类似物
KR20200057059A (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
AU2016232218A1 (en) Amylin analogues
JP6006264B2 (ja) グルカゴン類似体
JP5912150B2 (ja) グルカゴン類似体
JP2014210799A (ja) グルカゴン類似体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20181204

AD01 Patent right deemed abandoned